Sentences with phrase «in tumor therapy»
Until now the use of adenoviruses in tumor therapy has been very limited.
https://www.sciencedaily.com/ Not exact matches
«In the long term, we want to be able to send energy to and communicate with implants all over the body, to record data from a variety of organs in many different ways, maybe even report on the conditions of tumors or cancer therapies,» Maharbiz sayIn the long term, we want to be able to send energy to and communicate with implants all over the body, to record data from a variety of organs in many different ways, maybe even report on the conditions of tumors or cancer therapies,» Maharbiz sayin many different ways, maybe even report on the conditions of tumors or cancer therapies,» Maharbiz says.
• Tessa Therapeutics, a Singapore - based biopharmaceutical company focusing on T cell therapy for solid tumors, raised $ 80 million in funding.
Because the tumor chips can be printed, essentially, in unlimited supply, the possibility for fine - tuning a drug therapy is endless.
«This approval will open the floodgates for these kinds of therapy to be used in many different leukemias, lymphomas, solid tumors, myelomas,» Dr. Prakash Satwani, a pediatric hematologist - oncologist at Columbia University Medical Center, told Business Insider.
«We can look at the genes that are abnormal in brain tumors [and] develop therapies to attack those genes.»
The Kamens claim the main thing that distinguishes their foundation from other brain tumor foundations is their focus on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.
In December 2017, writing in Computer Methods in Applied Mechanics and Engineering, Yankeelov and collaborators at UT Austin and Technical University of Munich, showed that they can predict how brain tumors (gliomas) will grow and respond to X-ray radiation therapy with much greater accuracy than previous modelIn December 2017, writing in Computer Methods in Applied Mechanics and Engineering, Yankeelov and collaborators at UT Austin and Technical University of Munich, showed that they can predict how brain tumors (gliomas) will grow and respond to X-ray radiation therapy with much greater accuracy than previous modelin Computer Methods in Applied Mechanics and Engineering, Yankeelov and collaborators at UT Austin and Technical University of Munich, showed that they can predict how brain tumors (gliomas) will grow and respond to X-ray radiation therapy with much greater accuracy than previous modelin Applied Mechanics and Engineering, Yankeelov and collaborators at UT Austin and Technical University of Munich, showed that they can predict how brain tumors (gliomas) will grow and respond to X-ray radiation therapy with much greater accuracy than previous models.
In October 2016, writing in Mathematical Models and Methods in Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various therapieIn October 2016, writing in Mathematical Models and Methods in Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various therapiein Mathematical Models and Methods in Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various therapiein Applied Sciences, the team used a study of cancer in rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various therapiein rats to test 13 leading tumor growth models to determine which could predict key quantities of interest relevant to survival, and the effects of various therapies.
Gene therapy procedures in humans have been linked to the onset of leukemia and various tumors, as well as sudden death.
«We're trying to build models that describe how tumors grow and respond to therapy,» said Yankeelov, director of the Center for Computational Oncology at The University of Texas at Austin (UT Austin) and director of Cancer Imaging Research in the LIVESTRONG Cancer Institutes of the Dell Medical School.
This method, sometimes called «liquid biopsy,» can provide guidance for treatment decisions, monitoring of cancer therapy, and organism - wide screening for the presence of nascent metastatic tumors in drug - treated cancer patients.
In the spring, the U.S. Food and Drug Administration approved an antibody that is the first cancer therapy based on a tumor genetic biomarker instead of a location in the bodIn the spring, the U.S. Food and Drug Administration approved an antibody that is the first cancer therapy based on a tumor genetic biomarker instead of a location in the bodin the body.
Revving up the immune system to combat a wide variety of tumor types may take cancer therapy in a new direction, says Khaled Barakat, a computational scientist at the University of Alberta in Canada, who was not involved in the study.
«Used in cancer therapy, this process could increase the impact of a treatment by heating the cancer cells while introducing the drug compound into the tumor.»
The researchers confirmed some of these findings by analyzing how effective radiation therapy was in 29 colon cancer tumors that metastasized to either the liver or lung.
In melanoma, they can be used to determine tumor stage, diagnosis, therapy selection and when to monitor for disease recurrence.
On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.
Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy.
His team discovered that treatment - resistant melanoma tumors, in what is akin to drug addiction, develop a dependency on MAPK - targeted therapy to retain their fitness.
«Combination therapy strengthens T cells in melanoma pre-clinical study: Findings have implications for treating tumors lacking tumor suppressor gene PTEN.»
They then tried adoptive T cell therapy (ACT), in which T cells directed against a tumor are infused into a patient.
The experimental device is being tested in cancer patients to see whether it can be tuned to accurately measure tumor shrinkage in response to therapy.
In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions.
«Particularly in such patients with underlying CKD, our modeling results support the integration of renal tumor anatomic features at cross-sectional imaging into decision making for treatment of small renal masses and may be used to provide a patient - centered framework for selection of optimal candidates for ablative therapy,» Kang said.
«Current therapies in clinical trials are focused on targeting genetic changes in tumors and helping to boost one's immune system to fight the cancer cells.
This is one of the first research studies to highlight the importance of the location of the metastasis as well as the location of the original primary tumor, in predicting response to radiation therapy.
In particular, the study suggests that two miRNAs — miR - 4516 and miR - 601 — in tumor cells along with Gleason score and lymph node status may help identify patients who might experience rising PSA after they've been treated with radiation therapIn particular, the study suggests that two miRNAs — miR - 4516 and miR - 601 — in tumor cells along with Gleason score and lymph node status may help identify patients who might experience rising PSA after they've been treated with radiation therapin tumor cells along with Gleason score and lymph node status may help identify patients who might experience rising PSA after they've been treated with radiation therapy.
Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.
Conventional radiation with photons gave way to intensity - modulated radiation therapy, or IMRT, in which more precise beams of photons could be moved dozens or hundreds of times with varying intensities, attacking tumors in three dimensions with safer high doses.
Now, researchers at Washington University School of Medicine in St. Louis have shown that cervical tumors that don't respond to radiation may be vulnerable to therapies that also attack the cancer's fuel supply.
Restoring normal function to a mutated protein is more difficult than simply blocking a protein, the strategy used by most medical therapies, says Klas Wiman, a tumor cell biologist at the Karolinska Institute in Stockholm.
In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapieIn addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapiein cancer patients, with the intent of generating rational strategies for the creation of combination therapies.
This is particularly true for immunotherapy, in which characterization of tumor heterogeneity is essential for choosing the most effective therapy.
The Phase I clinical trial of OMP - 54F28 (FZD8 - Fc) is an open - label dose escalation study in patients with advanced solid tumors for which there was no remaining standard curative therapy.
The research team also tried the GD2 CAR - T therapy in mice with human spinal cord and thalamic tumors implanted in their respective anatomical locations.
In past imaging studies, my colleagues and I noticed that cervical tumors that took up a lot of glucose prior to radiation treatment tended to be more resistant to radiation therapy than other tumors.
Frequent, low - dose chemotherapy regimens avoid this effect and may therefore be more effective at treating certain types of breast and pancreatic cancer, according to the murine study «Metronomic chemotherapy prevents therapy - induced stromal activation and induction of tumor - initiating cells,» which will be published online November 23 in The Journal of Experimental Medicine.
«Considering that PDPN is associated with poor prognosis in GBM, CAR T - cell therapy that targets this protein is promising for treatment of patients with relapsed or resistant tumors following first - line chemotherapy,» says Toshihiko Wakabayashi, a coauthor and the chair of Department of Neurosurgery Nagoya University School of Medicine.
Importantly, while using rosiglitazone in conjunction with targeted therapy reduced tumor growth in both young and aged pre-clinical models, using rosiglitazone alone accelerated tumor growth in young models, while inhibiting it in aged ones.
EM: Imaging such as MRIs or CT scans, which reveal the mass and volume of the tumor, can fool you sometimes: The patient gets a scan, goes on a therapy, and when they return in a month for a second imaging, the structure and size of the tumor haven't changed.
«Genes may cause tumor aggressiveness, drug resistance in African - American prostate cancer: Research found many targeted therapies for prostate cancer may not be effective against tumors in African - American men.»
Wistar scientists have previously shown that age - related changes in the tumor microenvironment — or the surrounding area where tumor cells crosstalk with normal and immune cells — can drive melanoma progression and therapy resistance.
Tumor initiating cells (TICs, in red) are resistant to conventional chemo and radiation therapies.
With these in vitro test methods, the KU researchers have shown that anti-CD44s antibody can reduce pancreatic cancer cell growth, metastasis and ability of the tumors to recur after radiation therapy.
The team also compared the animals» responses to the therapy's effects in laboratory cell samples and found that in vitro studies did not predict how well the viral therapy and immune response would fight tumor cells in vivo.
Dr. Cripe and his colleagues at The Ohio State University, the University of Pittsburgh School of Medicine and Cincinnati Children's Hospital Medical Center tested how well the oncolytic viral therapy — a cancer - killing form of the herpes simplex virus, called oHSV — infected and killed tumor cells in mice with and without a healthy immune system.
When that common pathway was blocked with a new drug, mTOR inhibitor, in addition to continuing the optimized therapies, resistance was effectively turned off, and the tumors resumed shrinking.
Conventional therapies target rapidly dividing tumor cells, but are unable to eradicate the highly chemoresistant tumor initiating cells (TICs), ultimately responsible for relapse and spreading of the tumors in other parts of the body.
In the current study, Dr. Xu and colleagues gave radiation therapy to a mouse model of human pancreatic cancer to eradicate the bulk tumors, while only the cancer stem cells remained in the residual scarIn the current study, Dr. Xu and colleagues gave radiation therapy to a mouse model of human pancreatic cancer to eradicate the bulk tumors, while only the cancer stem cells remained in the residual scarin the residual scars.